We have previously found learning/memory, exercise intolerance, metabolic disturbance, gut dysbiosis and deregulation of neuroinflammatory genes, suggesting a possible microbiota-gut-brain interaction in GWI pathology (Kozlova et al., 2022a PMID: 34710444; 2022b PMID: 34801513). Here, we tested the hypothesis that probiotic treatment (P) prevents GWI symptoms. Adult male C57Bl/6N mice were separated into 4 groups (n=16/group): GW receiving pyridostigmine bromide (8.7 mg/kg, PB, po), permethrin (1.3 mg/kg, PER, top), DEET (33%, top); CON/S (vehicle plus stress); CON/S+P and GW+P. Probiotic groups received a gut-protective probiotic (P) cocktail of L. reuteri, L. rhamnosus, L. casei, B. longum (po, 108 CFU/mL, 3 times/wk) for 2 wk prior to and during GW agent treatment and until sacrifice 5 months later. Fecal RT-qPCR showed colonization of all strains except L. rhamnosus after 6-7 doses when compared to saline sham. Colonization after GW agent exposure was strain-specific and varied with time post-exposure. On an exercise endurance (EE) test GW (but not GW+P) mice tired faster relative to CON/S at PT56 (p<0.05) but not at PT150. Repeat testing on the passive avoidance apparatus (15 wk after previous test) showed that GW but not GW+P mice displayed reduced latency to enter aversive chamber on day 1 of acquisition trials, indicating deficient memory (p<0.05). Depressive-like behavior (mean percent time spent mobile) on tail suspension test (TST) showed less time spent mobile for GW (p<0.05) but not GW+P mice than controls at PT50 (but not PT150). Probiotics protected against the GW-induced rise in liver C-reactive protein (CRP) (p<0.05) and brain interleukin-6 (IL-6) (p<0.05). Immunofluorescence probing in the hippocampal CA1 and dentate gyrus showed significantly greater counts of Iba-1 positive cells in GW (but not GW+P) vs CON/S (p<0.05). NeuN immunostaining on the same sections showed abnormal neuronal phenotype indicative of reorganized RNA in GW but not GW+P) vs CON/S (p<0.05). Multi-gene profiling of innate and adaptive immunity genes in brain homogenates (prefrontal cortex, hypothalamus, hippocampus) identified GW agent-induced deregulation (>1.5-fold; p<.05) of pro-inflammatory genes, i.e., upregulation of C5ar1 and Cxcl10 and downregulation of Tlr4; changes prevented by probiotic treatment. In the gut, M1 proinflammatory macrophages appeared to be more abundant in GW (but not GW+P) vs CON/S (p<0.05). We used 16S next generation sequencing to examine probiotic treatment effects on gut microbial communities. In combination, our findings indicate that GW mice can be used to model multi-symptom illness and support previous evidence that the underlying pathophysiology in GWI likely involve systemic, gut and neuroinflammation and bacterial dysbiosis. Importantly, we show for the first time that probiotic treatment protects against some GWI symptom domains. Further study is needed to uncover pathophysiological pathways through which the microbiota-gut-brain axis impacts gut and brain health and toxicant-related pathology. DoD grant GW-180072 to M.C.C. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.